A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-Line Therapy of Post-Menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer.

Trial Profile

A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-Line Therapy of Post-Menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide; Hormones
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIDE
  • Sponsors Merck
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2012 Additional locations (Hungary, Sweden, Netherlands, Portugal, Ireland, France, Italy, Greece, Spain) added as reported by European Clinical Trials Database.
    • 31 Mar 2012 Planned number of patients changed from 909 to 1200 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top